October 2024
Senators Wyden and Brown Urge FTC to Expand Investigation into PBMs’ Anti-Competitive Practices
Pharmacy Benefit Managers (PBMs), Anti-Competitive Practices, FTC Investigation, Co-Manufacturing Agreements, Drug Prices, Healthcare Reform
IGM Biosciences Shifts Focus to Autoimmune Diseases Amid Leadership Changes
IGM Biosciences, autoimmune diseases, C-suite exits, biotechnology, immunology, arthritis, lupus
Kailera Secures $400M Funding to Advance China-Developed Obesity and Diabetes Therapies
Kailera, obesity, diabetes, China-developed drugs, $400M funding, pharmaceuticals, biotech
Gritstone Bio Explores Strategic Alternatives Amid Financial Strains and Mixed Cancer Vaccine Trial Results
Gritstone Bio, GRANITE, cancer vaccine, strategic alternatives, financial challenges, Phase 2 trial results
Pfizer Generates $2.88 Billion by Selling Off Hundreds of Millions of Haleon Shares
Pfizer, Haleon, share sale, pharmaceutical industry, financial news
Shattuck Labs Shifts Focus to IBD Drug, Discontinues CD47 Program and Reduces Workforce by 40%
Shattuck Labs, CD47 program, workforce reduction, IBD drug, SL-325, DR3 antagonist antibody
Metsera and Amneal Collaborate on Next-Generation Obesity Medicines, with Leadership Transition at Metsera
Metsera, Amneal, Obesity Drugs, Strategic Collaboration, Manufacturing Partnership, Leadership Transition
FDA Tracker: Fresenius Kabi and Formycon’s Stelara Biosimilar Set for 2025 Launch
Stelara biosimilar, Fresenius Kabi, Formycon, FDA approval, ustekinumab, Johnson & Johnson, J&J settlements, biosimilar competition
Prime Medicine Partners with Bristol Myers Squibb in $3.5B Cell Therapy Deal, Narrows Pipeline Focus
Prime Medicine, Bristol Myers Squibb (BMS), Cell Therapy, Gene Editing, Prime Editing, PASSIGE Technology, Ex Vivo T-Cell Therapies, Pipeline Reprioritization, Strategic Collaboration
Federal Judge Dismisses $6.4 Billion Lawsuit Against Bristol Myers Squibb Over Celgene Acquisition
Bristol Myers Squibb (BMS), Celgene Acquisition, $6.4 Billion Lawsuit, Contingent Value Rights (CVR), Federal Judge Ruling, Pharmaceutical Industry, Legal Dispute